Form 4: Anika Therapeutics Director John B. Henneman III Receives Significant RSU Grant

Anika Therapeutics, Inc. Director John B. Henneman III was granted 14,164 restricted stock units (RSUs) on June 20, 2025, as part of his compensation, aligning his interests with shareholder value.

Summary

• John B. Henneman III, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock on June 20, 2025.
• These shares were granted as Restricted Stock Units (RSUs) at a price of $0 per share, indicating they are part of compensation rather than a purchase.
• Each RSU represents a contingent right to receive one share of the Company's common stock.
• The RSUs are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.
• Following this transaction, Mr. Henneman beneficially owns 49,871 shares directly.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is generally a positive event as it aligns the director's interests with shareholders and is a standard form of compensation, indicating continued commitment. There are no negative financial implications beyond minor potential future dilution, which is typical.

Positives

• The grant of 14,164 Restricted Stock Units (RSUs) to Director John B. Henneman III aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The transaction represents an increase in the director's direct beneficial ownership, demonstrating continued commitment to the company.

Negatives

• The grant of 14,164 Restricted Stock Units (RSUs) could lead to minor future dilution for existing shareholders upon vesting, although this is a standard component of executive and director compensation.

Risks

• The value of the granted Restricted Stock Units (RSUs) is subject to the future market price fluctuations of Anika Therapeutics, Inc. common stock.
• The RSUs are contingent rights and will only convert to actual shares upon meeting the specified vesting conditions (earlier of 2026 annual meeting or June 20, 2026).

Future Outlook

The 14,164 Restricted Stock Units (RSUs) granted to Director John B. Henneman III are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026, at which point they will convert into shares of Anika Therapeutics, Inc. common stock.

Industry Context

This Form 4 filing reflects a standard practice in corporate governance where directors receive equity-based compensation, such as Restricted Stock Units (RSUs), to align their long-term interests with those of shareholders. Such grants are common across publicly traded companies in the biotechnology and medical device sectors, including Anika Therapeutics, Inc., as a means of attracting and retaining qualified board members.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of non-cash compensation in publicly traded companies, particularly within the healthcare and biotechnology sectors.
• The vesting schedule, tied to a future date or annual meeting, is typical for RSU grants, designed to encourage long-term commitment and performance.
• The specific number of RSUs granted (14,164) would need to be compared against the compensation practices of peer companies of similar market capitalization and industry focus to assess if it is within industry norms, but the document itself does not provide such comparative data.

Related Party Transactions

• The grant of 14,164 Restricted Stock Units (RSUs) to John B. Henneman III, a Director of Anika Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the RSUs, but also improved alignment of the director's interests with shareholder value.

Next Steps

• Vesting of the 14,164 Restricted Stock Units (RSUs) on the earlier of the 2026 annual meeting of Anika Therapeutics, Inc. stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, director compensation, equity grant, beneficial ownership